SoftBank China and Legend Capital both participated in a round that the gastrointestinal cancer diagnostics device developer will use to expand its R&D activities.
China-based cancer screening technology developer New Horizon Health has raised $20m in financing from investors including telecommunications firm SoftBank, China Money Network reported today.
SoftBank, which invested through its SoftBank China subsidiary, was joined by venture capital firm Qiming Venture Partners, which led the round, and Legend Capital, the investment firm sponsored by conglomerate Legend Holdings.
New Horizon is working on systems that will be able to screen for cancer at an early stage, and is particularly focusing on gastrointestinal…